Effect of 6-week Strawberry Supplementation on Insulin Action (STR2)

Insulin Resistance Clinical Trial

Official title:

Effect of 6 Weeks Strawberry Supplementation on Insulin Action and Associated Risk Factors in Insulin Resistant (IR) Subjects (STR2)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01457612
• Other study ID #: STR2 2011-076
• Status: Completed
• Phase: N/A
• Start date: October 1, 2011
• Est. completion date: March 1, 2013

Study information

• Verified date: February 2023
• Source: Clinical Nutrition Research Center, Illinois Institute of Technology
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary study objective is to investigate the potential chronic beneficial effect of polyphenolics derived from strawberry on impaired insulin signaling in insulin resistant individuals through their ability to modulate oxidative- and inflammatory-markers that lead to devastating disease, including, but not limited to, diabetes and cardiovascular disease.

Description:

This study is a single-center, randomized and single blinded, placebo-controlled, 6-week, parallel design study with follow-up to evaluate strawberry-associated chronic improvements in insulin action resulting in reduced whole body insulin resistance and improved glucose tolerance. This study will take approximately 11~12 weeks.

Subjects will follow an extremely limited polyphenolic diet throughout the duration of their participation in the study.

The limited diet will begin 7 days before the first study visit and end before the last study visit. Following the polyphenol-free 7-day run in period, at Week 0, subjects will be scheduled to return to the Center for sequence randomization, an Oral Glucose Tolerance Test (OGTT) as well as a Flow Mediated Dilation (FMD) procedure to measure endothelial function. Subjects will incorporate either one of tow Placebo Beverages (PBO1, n=15; PBO2, n=15) or Strawberry Beverage (STR, n=15, an optimal strawberry test dose of 40 g/d) into their diet daily for a period of 6 weeks. Subjects will consume randomly assigned beverage twice per day with their breakfast and dinner meals.

All subjects will be asked to come to the Center once a week where they will receive a week's supply of beverages. Additionally, fasting clinical and laboratory variables, anthropometrics, and vital sign measurements will be assessed at each bi-weekly visit at Week 3 and Week 5.

Participants will undergo the same procedures at the end of Week 6: fasting blood sample collection for analysis of insulin, glucose, oxidative and inflammatory markers, an OGTT to assess glucose handling, as well as a FMD procedure to assess endothelial function in response to 6 weeks of either the Placebo or Strawberry treatment.

Subjects will be required to visit the Center 4 weeks after the end of their intervention period (Week 10), at which time they will undergo their last anthropometrics and vital sign measurements, a 4 hour OGTT, and the FMD procedure.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 45
• Est. completion date: March 1, 2013
• Est. primary completion date: December 1, 2012
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Must meet ONE or MORE of the criteria (1)-(5) associated with insulin resistance along with all other criteria listed (6)-(9):

1. Blood glucose concentration between140-199 mg/dL at 2hr from OGTT.

2. Elevated fasting glucose (110 mg/dL= Fasting blood glucose <126 mg/dL)

3. Elevated fasting insulin (>75th percentile cutoff of 13.13 µU/mL)

4. Insulin resistance defined by the homeostasis model assessment method of insulin resistance (HOMA-IR) (glucose [in millimoles per liter] × insulin [in microunits per milliliter]/22.5) values of at least 2.5.

5. Waist circumference = 110 cm because many epidemiology studies have been shown that waist circumferences may be related to insulin resistance.

6. Nonsmokers

7. Not taking any medications that would interfere with outcomes of the study, i.e. lipid lowering medications, anti-inflammatory drugs, or dietary supplements

8. 18 years of age and older

9. No clinical evidence of cardiovascular, metabolic, respiratory, renal, gastrointestinal or hepatic disease

Exclusion Criteria:

• Pregnant and/or lactating.

• Allergy or intolerance to strawberries and dairy products.

• Current regular consumption of strawberries is > 2 servings per day.

• Fasting blood glucose = 126 mg/dL. Subjects identified with elevated fasting blood glucose levels will be advised to contact their primary care physician for appropriate follow-up care.

• Taking over the counter antioxidant supplements or other supplements that may interfere with the study procedures or endpoints.

• Subjects with unusual dietary habits (e.g. pica).

• Actively losing weight or trying to lose weight (unstable body weight fluctuations of > 5 kg in a 60 day period).

• Excessive exercisers or trained athletes.

• Subjects with documented atherosclerotic disease, inflammatory disease, diabetes mellitus, or other systemic diseases.

• Addicted to drugs and/or alcohol.

• Medically documented psychiatric or neurological disturbances.

• Smoker (past smoker may be allowed if cessation is > 2 years).

Related Conditions & MeSH terms

• Insulin Resistance
• Metabolic Disease
• Metabolic Diseases
• Nutrition Disorders
• Nutritional Disease

Intervention

Dietary Supplement:
• Strawberry
20g twice per day (BID) in beverage
• Placebo1
Placebo Beverage 1 without fiber
• Placebo2
Placebo Beverage 2 with Fiber

Locations

Country	Name	City	State
United States	Clinical Nutrition Research Center	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
Clinical Nutrition Research Center, Illinois Institute of Technology	California Strawberry Commission

Country where clinical trial is conducted

United States, 

References & Publications (2)

Burton-Freeman B, Linares A, Hyson D, Kappagoda T. Strawberry modulates LDL oxidation and postprandial lipemia in response to high-fat meal in overweight hyperlipidemic men and women. J Am Coll Nutr. 2010 Feb;29(1):46-54. doi: 10.1080/07315724.2010.107198 — View Citation

Edirisinghe I, Burton-Freeman B, Varelis P, Kappagoda T. Strawberry extract caused endothelium-dependent relaxation through the activation of PI3 kinase/Akt. J Agric Food Chem. 2008 Oct 22;56(20):9383-90. doi: 10.1021/jf801864t. Epub 2008 Sep 25. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The chronic beneficial effect of polyphenolics from strawberry on impaired insulin signaling in insulin-resistant men and women	Subjects will be randomized to receive either one of beverages, Pbo1, Pbo2 or Str Beverage and consume randomly assigned beverage twice per day with their breakfast and dinner meals for 6 weeks. On visits at Wk0, Wk6, and Wk10, blood will be collected at 0h, and 1h, 2h, 3h and 4h time points following the 75 g glucose load (oral glucose tolerance test) and Flow Mediated Dilation (FMD) procedure will be performed as well.	10 weeks
Secondary	The chronic beneficial effect of polyphenolics from strawberry on oxidative- and inflammatory-markers in insulin-resistant men and women	Samples of venous blood will be collected for measurement of oxidative and inflammatory markers (hs-CRP levels, LDL oxidation, Interleukin (IL)-6 and other inflammatory molecules, Total antioxidant levels of the blood)	10 Weeks